Beta-Sitosterol (purity>75%) (Synonyms: β-Sitosterol (purity>75%); 22,23-Dihydrostigmasterol (purity>75%))

目录号: HY-N0171B 一键复制产品信息纯度: 98.0%: Data Sheet SDS COA 产品使用指南
FAQs
技术支持

Beta-Sitosterol (purity>75%) 是一种具有口服活性的植物甾醇。Beta-Sitosterol (purity>75%) 可干扰多种细胞信号通路，包括细胞周期，细胞凋亡 (apoptosis) 和细胞增殖。Beta-Sitosterol (purity>75%) 有抗炎、抗氧化和抗肿瘤活性。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Beta-Sitosterol (purity>75%) Chemical Structure

CAS No. : 83-46-5

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
5 mg	￥175	In-stock
10 mg	￥280	In-stock
25 mg	￥525	In-stock
50 mg	￥840	In-stock
100 mg	￥1260	In-stock
200 mg		询价
500 mg		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Beta-Sitosterol (purity>75%) 相关产品

•同靶点产品:

•同靶点蛋白产品:

生物活性
纯度 & 产品资料
参考文献

生物活性

Beta-Sitosterol (purity>75%) is a phytosterol with oral activity. Beta-Sitosterol (purity>75%) interferes with a variety of cell signaling pathways, including the cell cycle, apoptosis and cell proliferation. Beta-Sitosterol (purity>75%) has anti-inflammatory, antioxidant, and antitumor activities^[1]^[2]^[3].

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
1A9	ED₅₀	10.6 μg/mL Compound: 17	Cytotoxicity against human 1A9 cells after 6 days by SRB assay Cytotoxicity against human 1A9 cells after 6 days by SRB assay	[PMID: 14640511]
1A9	ED₅₀	16.8 μg/mL Compound: 17	Cytotoxicity against human 1A9 cells after 3 days by SRB assay Cytotoxicity against human 1A9 cells after 3 days by SRB assay	[PMID: 14640511]
1A9/ptx-10	ED₅₀	20 μg/mL Compound: 17	Cytotoxicity against human 1A9/PTX10 cells after 3 days by SRB assay Cytotoxicity against human 1A9/PTX10 cells after 3 days by SRB assay	[PMID: 14640511]
1A9/ptx-10	ED₅₀	9.5 μg/mL Compound: 17	Cytotoxicity against human 1A9/PTX10 cells after 6 days by SRB assay Cytotoxicity against human 1A9/PTX10 cells after 6 days by SRB assay	[PMID: 14640511]
A2780	IC₅₀	> 10 μg/mL Compound: page 1629, R26C1	Cytotoxicity against human A2780 cells after 96 hrs by MTT assay Cytotoxicity against human A2780 cells after 96 hrs by MTT assay	[PMID: 17125236]
A549	ED₅₀	> 20 μg/mL Compound: 17	Cytotoxicity against human A549 cells after 3 days by SRB assay Cytotoxicity against human A549 cells after 3 days by SRB assay	[PMID: 14640511]
A549	IC₅₀	> 10 μg/mL Compound: page 1629, R26C1	Cytotoxicity against human A549 cells after 96 hrs by MTT assay Cytotoxicity against human A549 cells after 96 hrs by MTT assay	[PMID: 17125236]
BGC-823	IC₅₀	> 10 μg/mL Compound: page 1629, R26C1	Cytotoxicity against human BGC-823 cells after 96 hrs by MTT assay Cytotoxicity against human BGC-823 cells after 96 hrs by MTT assay	[PMID: 17125236]
Bel-7402	IC₅₀	> 10 μg/mL Compound: page 1629, R26C1	Cytotoxicity against human Bel-7402 cells after 96 hrs by MTT assay Cytotoxicity against human Bel-7402 cells after 96 hrs by MTT assay	[PMID: 17125236]
ECV-304	IC₅₀	472 μM Compound: Beta-sitosterol	Membrane toxicity against human ECV304 cells after 2 hrs by LDH release assay Membrane toxicity against human ECV304 cells after 2 hrs by LDH release assay	[PMID: 24084294]
ECV-304	IC₅₀	472 μM Compound: beta-sitosterol	Membranolytic activity in human ECV304 cells assessed as leakage of intracellular lactate dehydrogenase after 2 hrs by spectrophotometry Membranolytic activity in human ECV304 cells assessed as leakage of intracellular lactate dehydrogenase after 2 hrs by spectrophotometry	[PMID: 22503361]
ECV-304	IC₅₀	61 μM Compound: Beta-sitosterol	Cytotoxicity against human ECV304 cells after 72 hrs by MTT assay Cytotoxicity against human ECV304 cells after 72 hrs by MTT assay	[PMID: 24084294]
ECV-304	IC₅₀	61 μM Compound: beta-sitosterol	Cytotoxicity against human ECV304 cells after 72 hrs by Hoechst 33258 staining based fluorescence assay Cytotoxicity against human ECV304 cells after 72 hrs by Hoechst 33258 staining based fluorescence assay	[PMID: 22503361]
HCT-8	ED₅₀	> 20 μg/mL Compound: 17	Cytotoxicity against human HCT8 cells after 3 days by SRB assay Cytotoxicity against human HCT8 cells after 3 days by SRB assay	[PMID: 14640511]
HCT-8	IC₅₀	> 10 μg/mL Compound: page 1629, R26C1	Cytotoxicity against human HCT8 cells after 96 hrs by MTT assay Cytotoxicity against human HCT8 cells after 96 hrs by MTT assay	[PMID: 17125236]
HEp-2	IC₅₀	11.4 μM Compound: 119	Antiproliferative activity against human Hep2 cells by MTT assay Antiproliferative activity against human Hep2 cells by MTT assay	[PMID: 30830783]
HT-1080	IC₅₀	2.5 μM Compound: Angelicin	Cytotoxicity against human HT1080 cells assessed as reduction in cell viability Cytotoxicity against human HT1080 cells assessed as reduction in cell viability	[PMID: 30660827]
HUVEC	ED₅₀	> 5 μg/mL Compound: beta-sitosterol	Cytotoxicity against HUVEC Cytotoxicity against HUVEC	[PMID: 15043409]
HeLa	IC₅₀	46.22 μM Compound: 9	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 19447618]
J774	IC₅₀	> 241.1 μM Compound: 11	Cytotoxicity against mouse J774 cells by alamar blue assay Cytotoxicity against mouse J774 cells by alamar blue assay	[PMID: 17637068]
KB	ED₅₀	> 20 μg/mL Compound: 17	Cytotoxicity against human KB cells after 3 days by SRB assay Cytotoxicity against human KB cells after 3 days by SRB assay	[PMID: 14640511]
KB	IC₅₀	> 10 μg/mL Compound: 119	Antiproliferative activity against human KB cells assessed as reduction in cell viability Antiproliferative activity against human KB cells assessed as reduction in cell viability	[PMID: 30830783]
KB	IC₅₀	> 241.5 μM Compound: 119	Antiproliferative activity against human KB/HeLa cells assessed as reduction in cell viability Antiproliferative activity against human KB/HeLa cells assessed as reduction in cell viability	[PMID: 30830783]
LNCaP	ED₅₀	> 5 μg/mL Compound: beta-sitosterol	Cytotoxicity against human LNCAP cells Cytotoxicity against human LNCAP cells	[PMID: 15043409]
Lu1	ED₅₀	> 5 μg/mL Compound: beta-sitosterol	Cytotoxicity against human Lu1 cells Cytotoxicity against human Lu1 cells	[PMID: 15043409]
MCF7	ED₅₀	> 20 μg/mL Compound: 17	Cytotoxicity against human MCF7 cells after 3 days by SRB assay Cytotoxicity against human MCF7 cells after 3 days by SRB assay	[PMID: 14640511]
MCF7	ED₅₀	> 5 μg/mL Compound: beta-sitosterol	Cytotoxicity against human MCF7 cells Cytotoxicity against human MCF7 cells	[PMID: 15043409]
MCF7	IC₅₀	42.1 μM Compound: 9	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 19447618]
PC-3	ED₅₀	> 20 μg/mL Compound: 17	Cytotoxicity against human PC3 cells after 3 days by SRB assay Cytotoxicity against human PC3 cells after 3 days by SRB assay	[PMID: 14640511]
SK-MEL-1	IC₅₀	> 50 μM Compound: 9	Cytotoxicity against human SK-MEL-1 cells by MTT assay Cytotoxicity against human SK-MEL-1 cells by MTT assay	[PMID: 19447618]
U-87MG ATCC	ED₅₀	> 20 μg/mL Compound: 17	Cytotoxicity against human U87MG cells after 3 days by SRB assay Cytotoxicity against human U87MG cells after 3 days by SRB assay	[PMID: 14640511]
Vero	IC₅₀	> 128 μg/mL Compound: 4	Cytotoxicity against african green monkey Vero cells Cytotoxicity against african green monkey Vero cells	[PMID: 18818073]

体外研究
(In Vitro)

Beta-Sitosterol purity>75% (16 μM, 1, 3, 5 天) 可抑制 MDA-MB-231 人乳腺癌细胞生长和诱导细胞凋亡^[1]。
Beta-Sitosterol purity>75% (120, 240 μM, 24 h) 对 COLO 320 DM 细胞有明显的剂量依赖性生长抑制作用 (IC₅₀ 为 266.2 μM)。通过清除活性氧诱导细胞凋亡，抑制人结肠癌细胞中 β-catenin 和 PCNA 抗原的表达^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay^[1]

Cell Line:	MDA-MB-231
Concentration:	16 μM
Incubation Time:	3 days
Result:	No cytotoxicity at 16 μM

Apoptosis Analysis^[1]

Cell Line:	MDA-MB-231
Concentration:	16 μM
Incubation Time:	5 days
Result:	Increased 33% apoptosis when assayed using 1×10⁴ cells and a 6-fold increase in apoptosis when assayed using a smaller number of cells 5×10³.

Western Blot Analysis^[2]

Cell Line:	COLO 320 DM
Concentration:	15, 30, 60, 120 μM
Incubation Time:	24 h
Result:	Decreased β-catenin and PCNA expression.

体内研究
(In Vivo)

Beta-Sitosterol purity>75% (10-20 mg/kg, 混悬于 0.1% 的 CMC 中, 口服, 每天一次连续 16 周) 在结肠癌大鼠模型中具有预防癌变作用^[2]。
Beta-Sitosterol purity>75% (10, 15, 20 mg/kg, 口服, 连续 21 天) 在链脲佐菌素 (HY-13753) 诱导的实验性高血糖大鼠模型中有抗高血糖和抗氧化作用^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Colon cancer rats model ^[2]
Dosage:	10, 20 mg/kg
Administration:	p.o., suspended in 0.1% CMC (1.0 mL)
Result:	Reduced the number of aberrant crypt and crypt multiplicity in a dose-dependent manner.

Animal Model:	Streptozotocin-induced hyperglycemia rats model^[3]
Dosage:	10, 15, 20 mg/kg
Administration:	p.o.
Result:	Increased insulin levels and decreased HbA1c levels. Improved pancreatic antioxidant levels and decreased LPO levels.

分子量

414.71

Formula

C₂₉H₅₀O

CAS 号

83-46-5

性状

固体

颜色

White to off-white

结构分类

Steroids

初始来源

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

细胞实验：

DMF 中的溶解度 : 16.67 mg/mL (40.20 mM; 超声助溶 (<60°C))

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.4113 mL	12.0566 mL	24.1132 mL
5 mM	0.4823 mL	2.4113 mL	4.8226 mL
10 mM	0.2411 mL	1.2057 mL	2.4113 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMF 90% Corn Oil
Solubility: ≥ 1.67 mg/mL (4.03 mM); 澄清溶液

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

计算结果

工作液所需浓度 : mg/mL

纯度 & 产品资料

纯度: 98.0%

选择批次：

Data Sheet (630 KB) SDS (393 KB)

COA (290 KB) HNMR (263 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Awad AB, et al. Inhibition of growth and stimulation of apoptosis by beta-sitosterol treatment of MDA-MB-231 human breast cancer cells in culture. Int J Mol Med. 2000 May;5(5):541-5. [Content Brief]

[2]. Baskar AA, et al. Chemopreventive potential of beta-Sitosterol in experimental colon cancer model--an in vitro and In vivo study. BMC Complement Altern Med. 2010 Jun 4;10:24. [Content Brief]

[3]. Gupta R, et al. Antidiabetic and antioxidant potential of β-sitosterol in streptozotocin-induced experimental hyperglycemia. J Diabetes. 2011 Mar;3(1):29-37. [Content Brief]

Beta-Sitosterol (purity>75%) 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMF	1 mM	2.4113 mL	12.0566 mL	24.1132 mL	60.2831 mL
	5 mM	0.4823 mL	2.4113 mL	4.8226 mL	12.0566 mL
	10 mM	0.2411 mL	1.2057 mL	2.4113 mL	6.0283 mL
	15 mM	0.1608 mL	0.8038 mL	1.6075 mL	4.0189 mL
	20 mM	0.1206 mL	0.6028 mL	1.2057 mL	3.0142 mL
	25 mM	0.0965 mL	0.4823 mL	0.9645 mL	2.4113 mL
	30 mM	0.0804 mL	0.4019 mL	0.8038 mL	2.0094 mL
	40 mM	0.0603 mL	0.3014 mL	0.6028 mL	1.5071 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Beta-Sitosterol (purity>75%)83-46-5β-Sitosterol (purity>75%) 22,23-Dihydrostigmasterol (purity>75%)ApoptosisMDA-MB-231COLO 320 DMColon cancer rats modelStreptozotocin-induced hyperglycemiaInhibitorinhibitorinhibit

您最近查看的产品:

产品名称：

* 需求量：

* 客户姓名：

* Email：

* 电话：

* 公司或机构名称：

留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
粤ICP备2021105330号-3 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2026 MedChemExpress. All Rights Reserved.

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。

站点地图隐私声明

粤ICP备2021105330号-3